{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009224","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.197652+00:00","generated_at":"2026-06-05T01:40:26.125667+00:00","sec_items":["2.03","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AgeX draws $500K, sets warrant dividend and reverse split for Serina merger","bullets":["Drew $500,000 under secured convertible note with Juvenescence; repayment due May 9, 2024.","Declared warrant dividend: three Post-Merger Warrants per five shares held, exercise price $13.20, expiring July 31, 2025.","Reverse stock split expected March 14, 2024; trading on split-adjusted basis March 15, 2024.","Special meeting on March 14, 2024 to vote on warrant dividend and reverse stock split."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009224","json":"https://secwatch.observer/filing/0001493152-24-009224.json","markdown":"https://secwatch.observer/filing/0001493152-24-009224.md","text":"https://secwatch.observer/filing/0001493152-24-009224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009224/0001493152-24-009224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009224/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:40:26.125667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3be73c0a90a4d07977ec61344d0b5314d21b1111","claim":"Serina Therapeutics, Inc. incurred loan of $500,000 with Juvenescence Limited maturing May 9, 2024.","evidence_excerpt":"On March 5, 2024, AgeX Therapeutics, Inc., a Delaware corporation (“AgeX”), drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended ( the “Secured Note”), with Juvenescence Limited.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009224/0001493152-24-009224-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Maturity","value":"May 9, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}